Приказ основних података о документу

dc.creatorMiljković, Milica
dc.creatorStefanović, Aleksandra
dc.creatorBogavac-Stanojević, Nataša
dc.creatorSimić-Ogrizović, Sanja
dc.creatorDumić, Jerka
dc.creatorCerne, Darko
dc.creatorJelić-Ivanović, Zorana
dc.creatorKotur-Stevuljević, Jelena
dc.date.accessioned2019-09-02T11:59:33Z
dc.date.available2019-09-02T11:59:33Z
dc.date.issued2017
dc.identifier.issn0353-9466
dc.identifier.urihttps://farfar.pharmacy.bg.ac.rs/handle/123456789/2886
dc.description.abstractInflammation, apoptosis and extracellular remodeling play significant roles in cardiovascular disease (CVD) underlying the major causes of mortality in renal patients. In 19 pre-dialysis patients, 21 dialysis patients and 20 control subjects, the concentrations of pentraxin-3, galectin-3, MMP-9 and TIMP-1 were determined by ELISA. CVD risk was calculated according to the Framingham risk score algorithm. Pentraxin-3 was increased in renal patients compared to healthy controls (p lt 0.001). In contrast, galectin-3 was reduced in hemodialysis patients compared to pre-dialysis patients and controls (p lt 0.001). In addition, MMP-9 and TIMP-1 were elevated in renal patients compared to controls (p lt 0.01 and p lt 0.001, respectively). Logistic regression analyses disclosed associations of galectin-3, MMP-9, pentraxin-3 and glomerular filtration with calculated CVD risk score. Combined testing of pentraxin-3, galectin-3, MMP-9 and glomerular filtration rate can discriminate renal patients with high and low risk of a coronary event.en
dc.publisherSestre Milosrdnice Univ Hospital, Zagreb
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/175035/RS//
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceActa Clinica Croatica
dc.subjectKidney diseasesen
dc.subjectPentraxin-3en
dc.subjectGalectin-3en
dc.subjectMatrix-metalloproteinase-9en
dc.subjectTissue inhibitor of matrix metalloproteinase-1en
dc.subjectRisk factorsen
dc.subjectRisk assessmenten
dc.subjectCardiovascular diseasesen
dc.titleAssociation of pentraxin-3, galectin-3 and matrix metalloproteinase-9/TIMP-1 with cardiovascular risk in renal disease patientsen
dc.typearticle
dc.rights.licenseBY-NC-ND
dcterms.abstractКотур-Стевуљевић, Јелена; Симић-Огризовић, Сања; Јелић-Ивановић, Зорана; Богавац-Станојевић, Наташа; Миљковић, Милица; Стефановић, Aлександра; Думић, Јерка; Церне, Дарко;
dc.citation.volume56
dc.citation.issue4
dc.citation.spage673
dc.citation.epage680
dc.citation.other56(4): 673-680
dc.citation.rankM23
dc.identifier.wos000426891900014
dc.identifier.doi10.20471/acc.2017.56.04.14
dc.identifier.pmid29590722
dc.identifier.scopus2-s2.0-85042388871
dc.identifier.fulltexthttps://farfar.pharmacy.bg.ac.rs//bitstream/id/1509/2884.pdf
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу